HERNDON, Va.--(BUSINESS WIRE)--Feb. 10, 2004--ASCEND Therapeutics, Inc. announced today the formation of its Scientific Advisory Board. This board brings to ASCEND significant expertise in the areas of endocrinology, breast disease, drug delivery and regulatory affairs.
The initial members of the ASCEND board are:
Dr. Carl Peck, M.D., Founder of the Center for Drug Development Science (CDDS) and Professor of Pharmacology and Medicine at Georgetown University Medical Center. Dr. Peck is a recognized authority in drug regulatory science. From 1987-1993, Dr. Peck was Director of the FDA's Center for Drug Evaluation and Research (CDER). In this position, he oversaw the submission, review and approval process for all INDs, NDAs and ANDAs submitted to the FDA. After leaving the FDA, Dr. Peck established the CDDS. This Center has served as an important resource for innovation in drug development. Adrian Dobs, M.D., M.H.S., Professor and Vice Chair for Clinical Research, Departments of Medicine, Endocrinology and Metabolism at The Johns Hopkins University. In this role, Dr. Dobs oversees all of the university's clinical studies. She is a recognized endocrine authority and leading clinical research scientist in the area of testosterone therapy for both men and women.
Rogerio Lobo, M.D., the Willard C. Rappleye Professor of Obstetrics and Gynecology and a director of the Center for Reproductive Sciences at Columbia Presbyterian Medical Center. Dr. Lobo is an internationally known expert in the field of reproductive endocrinology. He is the author of Treatment of Postmenopausal Women and serves as Editor-in-Chief of the Journal of the Society for Gynecologic Investigation. He is a member of the advisory committee on policy of the American Journal of Obstetrics and Gynecology and serves on the editorial boards of several obstetric and gynecological journals. Robert Mansel, M.S., F.R.C.S., Professor of Surgery and Chairman of the Division of Surgery at the University of Wales College of Medicine in Cardiff, Wales. Professor Mansel specializes in the field of breast cancer and benign breast disease. He has authored numerous publications on benign breast disease, sentinel node biopsy breast cancer trials, tamoxifen prevention therapy and genetic studies in high-risk breast cancer families. He is joint author of a textbook on benign breast disease. Russell Potts, Ph.D., Adjunct Professor in the Department of Pharmacy at the University of California at San Francisco. Dr. Potts previously served as Vice President of Research and Development of Cygnus, a company known for the development and manufacture of advanced transdermal drug delivery systems, such as Nicotrol®. Over the last 20 years, Dr. Potts has pursued both an academic and pharmaceutical with industry career in the fields of dermal drug delivery and medical devices, Potts developed qualitative methodology to predict skin permeability. He is the author of numerous publications, including The Mechanisms of Transdermal Drug Delivery.
Ronald Swerdloff, M.D., Professor of Medicine and Chief of the Division of Endocrinology in the Department of Medicine at UCLA. He is a leading expert on men's health and androgen research and has published more than 250 articles on the subject. Currently, Dr. Swerdloff is Director of the Mellon Center for Men's Health, Director of the WHO Collaborating Center for Research in Human Reproduction and Chairman of the National Klinefelter's Society Scientific Committee. He is also a member of the NIH Safety Advisory Committee of the National Aging Institute. "We are delighted to have assembled such a prestigious group of individuals to serve as our Scientific Advisory Board," noted Jay Bua, Chief Executive Officer of ASCEND Therapeutics. "We believe the cumulative expertise of this group will be of great value to ASCEND as we further develop and commercialize our products."
Formed in 2001, ASCEND (www.ascendtherapeutics.com) s an emerging biopharmaceutical company focused on the use of transdermal drug delivery technology to overcome therapeutic barriers and thereby raise the standard of care for certain chronic conditions.
For more information, visit ASCEND's web site at www.ascendtherapeutics.com.
LaVoie Strategic Communications Group, Inc. Paul Kidwell, 781-596-0200 X104 email@example.com
Source: ASCEND Therapeutics, Inc.